Emglev Therapeutics

Uses a proprietary next-generation synthetic antibody platform to discover and develop transformative immunotherapies addressing unmet medical needs in oncology.
Emglev Therapeutics was acquired by Valerio Therapeutics in September 2024 and is now a subsidiary operating under the name Valour Bio. Spin-off from the Institut Curie.